The optimal regimen of brentuximab vedotin for CD30⁺ cutaneous lymphoma: are we there yet?

Br J Dermatol. 2018 Feb;178(2):571. doi: 10.1111/bjd.16052. Epub 2017 Dec 18.

Authors

S Geller¹, P L Myskowski¹, Y H Kim², A Moskowitz³, S Horwitz³

Affiliations

¹ Dermatology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medicine, New York, NY, U.S.A.
² Department of Dermatology, Stanford University School of Medicine, Stanford, CA, U.S.A.
³ Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medicine, New York, NY, U.S.A.

PMID: 29023638
DOI: 10.1111/bjd.16052

No abstract available

Publication types

Letter
Comment

MeSH terms

Brentuximab Vedotin
Hodgkin Disease
Humans
Immunoconjugates*
Ki-1 Antigen*
Lymphoma, Follicular

Substances

Immunoconjugates
Ki-1 Antigen
Brentuximab Vedotin